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Primary prevention in individuals at Clinical High Risk for psychosis (CHR-P) can
ameliorate the course of psychotic disorders. Further advancements of knowledge
have been slowed by the standstill of the field, which is mostly attributed to its
epidemiological weakness. The latter, in turn, underlies the limited identification power
of at-risk individuals and the relatively modest ability of CHR-P interviews to rule-in a
state of risk for psychosis. In the first part, this perspective review discusses these
limitations and traces a new approach to overcome them. Theoretical concepts to
support a Psychosis Polyrisk Score (PPS) integrating genetic and non-genetic risk and
protective factors for psychosis are presented. The PPS hinges on recent findings
indicating that risk enrichment in CHR-P samples is accounted for by the accumulation
of non-genetic factors such as: parental and sociodemographic risk factors, perinatal
risk factors, later risk factors, and antecedents. In the second part of this perspective
review we present a prototype of a PPS encompassing core predictors beyond genetics.
The PPS prototype may be piloted in the next generation of CHR-P research and
combined with genetic information to refine the detection of individuals at-risk of
psychosis and the prediction of their outcomes, and ultimately advance clinical research
in this field.
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HIGHLIGHTS
– Research in individuals at Clinical High Risk for Psychosis is at a standstill.
– Limitations include low detection power and suboptimal prognostic accuracy.
– Psychosis Polyrisk Scores (PPS) have the potential to improve the detection of at-risk individuals.
– Psychosis Polyrisk Scores (PPS) have the potential to optimize the prediction of psychosis.
Oliver et al. PPS for Psychosis Risk Prediction
INTRODUCTION
Psychotic disorders such as schizophrenia are among the world’s
leading causes of disability from psychiatric disorders (1). Under
standard care, outcomes of psychosis are relatively poor (2).
The implementation of early intervention services for patients
experiencing their first episode of illness may improve the course
of the disorder (3). However, recent meta-analytical evidence
indicates there is no robust evidence that these services can
effectively prevent psychotic relapse (3) or reduce the duration
of untreated psychosis (4). Thus, there are high expectations that
primary prevention in individuals who have not yet experienced
the disorder can ameliorate its course (5). In clinical practice,
such a strategy has been limited to indicated prevention that
is offered to individuals at Clinical High Risk for Psychosis
[CHR-P (6)]. The definitions and description of specific CHR-P
instruments have been fully presented in previous publications
(7). In brief, the CHR-P state defines a condition of liability
toward the development of incident psychotic disorders, but
not of any other incident non-psychotic mental disorder (8,
9). CHR-P research has allowed the study of the factors that
predate the onset of psychosis and experimental therapeutics
to be trialed for the prevention of psychosis (e.g., omega-
3 fatty acids (10, 11). However, its impact on improving
the outcomes of psychotic disorders has been constrained by
significant limitations. The present perspective review originates
from a critical analysis of these limitations and confronts this
in two sections. In the first part, it traces a new conceptual
avenue for future research—tackling the above constraints by
formulating the theoretical groundwork. In the second part, a
practical prototype of a new prognostic tool is introduced to
inform the future development of more efficient strategies to
detect individuals at-risk for psychosis and the prediction of
their outcomes.
METHODS
For the first part, a critical review of the past literature was
conducted. Relevant articles were retrieved through international
databases (PubMed, books, meetings, abstracts, electronic
guidelines, and international conferences) and critically reviewed
by the authors of the paper. Subsequently, results were presented
after reaching a consensus and were summarized through
illustrative tables and figures. This review is not following
a systematic literature search, data extraction, or reporting
approach, since its ultimate aim is to provide a conceptual
perspective of the field. In the second part, we applied the
concepts refined through the critical literature search to the
field of psychosis prediction. We thus operationalize a Psychosis
Polyrisk Score (PPS) and present it. Simulation analyses
complemented our approach to provide some initial feasibility
and prognostic values associated with the use of the PPS. Further
details of the operationalization of the PPS and how simulation
analyses were conducted can be seen in section “Psychosis
Polyrisk Score (PPS) Prototype”.
CONCEPTUAL REVIEW OF THE
LIMITATIONS OF THE CLINICAL HIGH
RISK STATE FOR PSYCHOSIS
The Epidemiological Weakness of the
Clinical High Risk State for Psychosis
To illustrate the epidemiological weakness associated with the
CHR-P paradigm we present data from our experience of
detecting and providing clinical care to these individuals in
South London (12). First, by using validated population-level
prediction tools (e.g., www.psymaptic.org), we estimated the
annualized incidence of psychotic disorders in the local general
population (13). The recruitment of individuals who may be at
CHR-P for psychosis is primarily based on unstructured selection
and sampling strategies that are based on clinician’s suspicion
of psychosis risk (14) and on help-seeking behaviors (15).
Therefore, the way these individuals are sampled will determine
their level of accumulation of risk factors for psychosis. For
example, when individuals undergoing a CHR-P assessment are
recruited from mental health services, they accumulate several
risk factors for the disorder (16) which increase their level of
risk to 15% at 3-years, compared to the 0.43% 3-year risk in
the local age-matched general population (12, 17) (Figure 1).
This level of risk is also termed as “pre-test risk,” because it is
ascertained in the whole group of people undergoing a CHR-P
assessment before the results of the assessment itself are known
(19). Therefore, the level of risk of samples undergoing a CHR-
P assessment does not reflect the level of risk of the general
population, but it is substantially higher: from 0.43% at 3-year
to 15% at 3-year (about 35-fold-higher). Once these individuals
complete a CHR-P assessment, they will be predicted to have
a certain post-test risk of developing psychosis or not. Thus,
pre-test and post-test risks of psychosis index an individual’s
likelihood of developing psychosis before and after the results
of the CHR-P assessment are known, respectively (19). It follows
that the value of a test will depend on its ability to alter (increase
or decrease) a pre-test probability of a target condition into a
post-test probability that will influence a clinical management
decision (20). When these individuals with a 15% pretest risk
at 3-year are assessed (tested), those who will meet CHR-P
criteria will have a 26% risk of developing psychosis at 3-year
(1.7-fold increase) and those who will not meet the CHR-P
criteria will have a 1.56% risk of developing psychosis at 3-year
(10-fold decrease) (Figure 2). The relationship between the risk
enrichment accounted by the recruitment step (pre-test) and
diagnostic assessment step (post-test) (19) is illustrated in specific
charts (Nomograms) that have been externally validated (23).
It confirms that once individuals are recruited for undergoing
a CHR-P assessment, there is only limited prognostic gain in
meeting the CHR-P criteria (i.e., testing positive to the interview),
while there is some prognostic gain in not meeting the CHR-
P criteria (i.e., testing negative to the interview). In other
words, the CHR-P tools are quite good at ruling out a state
of psychosis risk but not very good at ruling it in; they can
only be clinically meaningful when applied to samples that have
been risk-enriched. When different CHR-P instruments (7) or
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FIGURE 1 | Individuals seeking help at specialized psychosis early-detection clinics have a higher (pre-test) risk of developing psychosis [15% at 3 years (14)] than the
general population (0.43% at 3 years) (17). Those who will meet the clinical high risk for psychosis (CHR-P) criteria at the prognostic interview (Comprehensive
Assessment of At-risk Mental States [CAARMS]) will have only a modest increase in their (post-test) level of risk for psychosis (1.7-fold, from 15 to 26%). Those not
meeting the CHR-P criteria (18) will have a substantial decrease in their (post-test) risk (10-fold, from 15 to 1.56%).
even the DSM-5 category of Attenuated Psychosis Syndrome,
-which is not psychometric-based and therefore not strictly
speaking a CHR-P instrument- are applied to these samples, they
produce comparable prognostic performance (24, 25). As shown
in Figure 3, the actual risk of developing psychosis in CHR-P
samples is thus largely dependent on the way individuals are
recruited for the assessment and on their pre-test risk enrichment
(14, 17). The additional challenge is that recruitment strategies
for individuals undergoing CHR-P assessment and therefore pre-
test risk enrichment are highly heterogeneous, idiosyncratic and
poorly standardizable (14). This results in a high variance of
risk enrichment across samples undergoing CHR-P assessment
[meta-analytical 48-months risk of psychosis 95%CIs 0.09–0.24
(14), Figure 3]. Therefore, CHR-P samples that undergo distinct
psychosis risk enrichment pathways are hardly comparable as
they are likely to have different profiles of risk factors (26, 27).
These notions have both clinical and research implications. On
a clinical level, the variable risk enrichment of CHR-P samples
may amplify variations in patients’ clinical needs and limit the
provision of standard clinical care. On a research level, CHR-P
samples with little risk enrichment or heterogeneous risk profiles
may lead to negative findings in neurobiological studies (28)
or even in preventative trials (29–31). Overall, because of these
points, the key limitation of the CHR-P paradigm is currently that
of substantial epidemiological weakness (27, 32).
Idiosyncratic Accumulation of Risk Factors
in Individuals With a Clinical High Risk
State for Psychosis
Risk factors contributing to the psychosis risk enrichment
observed in CHR-P samples are not entirely known. A recent
meta-analysis has summarized the available evidence across
54 putative risk factors investigated in CHR-P samples, in
comparison to controls (16). Astoundingly, there are no existing
studies on the association between genetic or epigenetic risk
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FIGURE 2 | Sampling procedure for individuals at clinical high risk for
psychosis (CHR-P) (14). Idiosyncratic recruitment strategies that are
characterized by heterogeneous sampling biases (convenience and
judgmental sampling) result in the accumulation of various risk factors for
psychosis and differential level of enrichment of psychosis risk. The figure is
based on the data reported in Fusar-Poli et al. (17), Fusar-Poli (21), and
Rutigliano et al. (22). CAARMS, Comprehensive Assessment of At Risk Mental
States; SIPS, Structured Interviews for Psychosis-Risk Syndromes;
DSM-5-APS, Diagnostic and Statistical Manual, 5th Edition, Attenuated
Psychosis Syndrome. Adapted from: Fusar-Poli et al. (12).
factors and the CHR-P state. Although family history for
psychosis is partially embedded in CHR-P criteria, its predictive
significance within the CHR population is questionable. A
recent collaborative meta-analysis has found that CHR-P
individuals with a familial history of psychosis do not have an
enhanced risk of developing psychosis within 4 years follow-up,
compared to controls (33). Essentially, the above meta-analysis
showed that CHR-P subjects are more likely to show obstetric
complications, tobacco use, physical inactivity, childhood
trauma, high perceived stress, childhood and adolescent low
functioning, affective comorbidities, male gender, single status,
unemployment, and low educational level as compared to
controls (16). Overall, this study suggests that risk enrichment
of CHR-P samples can be attributed to demographic and
environmental risk factors like childhood trauma, adverse life
events and affective dysfunction. The differential combination
of risk/protective factors in each CHR-P individual is likely to
account for the distinct clinical outcomes observed in these
samples: psychosis onset, recovery, or disability (6).
Limited Detection Power
An additional problem is that the risk profiles observed in
CHR-P individuals who will develop psychosis may not be
representative of a prototypical first episode of psychosis. CHR-
P individuals who later transition to psychosis represent only
about 5% of first episode patients within secondary mental health
care (34). This suggests there is limited detection power for
at-risk cases and inefficient recruitment strategies (5). Such a
limitation is substantial, undermining the significance of the
entire paradigm. Although CHR-P interviews are particularly
good at ruling out psychosis, only a minority of individuals
are referred for a full CHR-P assessment. The alternative
approach of using CHR-P instruments to screen all individuals
accessing secondary mental health care is logistically untenable
(5). These limitations of knowledge can be tackled through a
refined approach for the detection of at-risk individuals and
the prediction of psychosis. Recent studies have developed and
externally validated individualized risk prediction tools that
depend on few established risk factors for psychosis (34–36), with
the ultimate goal of improving the detection of at-risk cases. This
line of research can be further expanded through the integration
of recent epidemiological research on genetic risk factors,
demographic and environmental risk factors for psychosis.
Implications for Neuroscience and
Behavioral Research
The above limitations have a profound impact on neurobiological
research conducted in CHR-P samples. Idiosyncratic recruitment
strategies lead to uncontrolled accumulation of risk and
protective factors and increase the clinical heterogeneity of CHR-
P samples (33). In turn, the high clinical heterogeneity has
hampered the discovery of reliable and replicable biomarkers of
psychosis risk (21). As summarized in Figure 3, CHR-P samples
that had been largely recruited through the community (37)
showed a dilution in pre-test risk (14) with a resulting lack of gray
matter abnormalities, when compared to controls (28). Because
of these issues, no reliable neuroimaging, electrophysiological or
neurocognitive biomarker of psychosis risk has been validated
for clinical use in CHR-P samples yet. Furthermore, the limited
detection power of the current recruitment strategies adds
concerns, undermining the assumption that the neurobiological
alterations reported in CHR-P individuals would represent
prototypical features preceding the onset of psychosis (3).
THE EXAMPLE OF POLYGENIC RISK
SCORE
High heritability of psychotic disorders, such as schizophrenia,
indicates a substantial impact of inherited genetic variants on
risk. Although genetic variants can be common or extremely
rare, nearly one-third of the genetic risk of schizophrenia
is indexed by common alleles genotyped through arrays in
genome-wide association studies (GWAS) (38). As each marker
individually explains only a small proportion of the genetic
variation, recent research has developed polygenic risk scores
in order to examine disorder prediction by genetic variants “en
masse,” summarizing risk variants across many associated loci
into quantitative scores (39). Such an approach requires robust
a priori knowledge on the association between specific loci and
psychosis as a first step (38). The polygenic risk score was
therefore grounded on the GWAS meta-analysis conducted by
the Schizophrenia Working Group of the Psychiatric Genomics
Consortium (38). This meta-analysis identified that despite the
small effect sizes of single loci, the cumulative effect of thousands
of schizophrenia-associated loci expressed a polygenic risk score
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FIGURE 3 | Effect of sampling biases in the CHR-P paradigm. Idiosyncratic recruitment strategies lead to differential accumulation of risk factors for psychosis across
samples undergoing CHR-P assessment. For example, recruiting from secondary mental health care (sample 1) is associated with high risk enrichment for psychosis
(also termed “pretest” risk) compared to recruiting from the general practitioners (sample 2), while no or little psychosis-risk enrichment is observed if the sample is
randomly selected from the general population (sample 3). Applying the CHR-P interviews to these samples discriminates between those at-risk for psychosis and
those not at-risk (post-test risk). However, the actual (post-test) transition to psychosis that is observed at follow-up largely depends on the overall level of
accumulation of risk factors for psychosis during the risk enrichment phase and only in minor part on the results (i.e., testing at-risk or not at-risk) of the CHR-P
assessment itself.
explained up to 18% of variance between cases of schizophrenia
and controls in GWAS studies and 7% of the variance on
the underlying liability scale to schizophrenia in the general
population (38). Polygenic risk scores have been used to predict
case-control status at the time of a first episode psychosis,
explaining nearly 9% of variance (39). However, as heritability of
schizophrenia is 64% (95%CI: 62–68%) (40), a large proportion
of the variance remains unaccounted. As the variance explained
is too small for individual risk prediction, the use of polygenic
risk scores in clinical routine is currently insufficient on its
own (38, 41).
TOWARD A POLYRISK SCORE
ENCOMPASSING NON-GENETIC
RISK/PROTECTIVE FACTORS
Given the small proportion of variance explained, risk prediction
needs to be boosted by supplementing the polygenic risk
scores with additional information. The model that has
received some empirical support indicates that the etiology of
psychotic disorders like schizophrenia involves direct genetic and
environmental effects, along with their interaction (42, 43). In
reality, some of the most predictive factors, including family
history of mental illness and socioeconomic status, include both
a genetic and environmental component and hence a distinction
between genetic and environmental factors may be spurious.
We will, therefore, adopt a pragmatic approach and use the
term non-genetic to define sociodemographic, social, parental,
perinatal, later risk or protective factors, or antecedents -see
below-. The use of a priori clinical knowledge is a robust method
for developing a clinical prediction model [for a review on this
see (44)].
Definition of Risk and Protective Factors
for Psychosis
For descriptive purposes, in the current manuscript
risk/protective factors for psychotic disorders are grouped
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FIGURE 4 | Putative model of the onset and progression of psychosis in relation to non-purely genetic risk factors and developmental processes affected by the
disorder. Sociodemographic and parental risk factors and perinatal risk factors have been implicated during the preclinical phase, usually observed from the birth to
infancy, childhood and early adolescence. Additional later factors occurring during later adolescence and early adulthood can trigger the onset of attenuated psychotic
symptoms, functional impairment and help-seeking behavior, which constitute the CHR-P stage. The diagnosis of psychosis, which operationally corresponds to the
first episode of psychosis, is usually made during the adolescence or early adulthood, with a peak from 15 to 35 years (48). Once diagnosed, psychosis usually
follows a fluctuating course punctuated by acute exacerbation of psychotic crises superimposed upon a background of poorly controlled negative, neurocognitive,
and social cognitive symptoms. The pink boxes represent the risk factors for psychosis as identified by the umbrella review (48). There is no assumption that these risk
factors are of causal nature or that they are independent of each other. Furthermore, certain risk factors may actually represent outcomes of earlier risk factors. Figure
based on the data reported in Fusar-Poli et al. (16). FEP, First Episode Psychosis; CHR-P, Clinical High Risk for Psychosis.
across domains previously defined: sociodemographic and
parental factors, perinatal factors, later factors, and antecedents
(45–47). Demographic, parental, social, and perinatal risk
factors are generally believed to exert their role during the
early developmental phases that precede the onset of psychosis
(see also Figure 4). On the contrary, later risk factors and
antecedents are believed to modulate psychosis risk in the
post perinatal period, from late childhood up to the phases
that shortly precede the onset of a psychotic disorder. While
later risk factors would indicate a passive exposure to socio-
environmental factors, antecedents would index premorbid
deviations in functioning and developmental milestones and
active risk-modifying processes involved in psychosis onset
(45–47). However, the boundaries of these categories may in
fact overlap.
Evidence and Classification of Risk and
Protective Factors for Psychosis
The inclusion of non-genetic factors in the development of
polyrisk scores is not a conceptually novel approach, but it
has been limited to date by the lack of established and robust
a priori knowledge on the association of non-genetic factors
and psychotic disorders. Such a limitation has been recently
overcome by an umbrella review, which is a meta-analysis
of meta-analyses or reviews, investigating several non-genetic
risk/protective factors of psychosis that operate at an individual
level. The umbrella review further classified these factors into
convincing (class I), highly suggestive (class II), suggestive (class
III), weak (class IV), and non-significant (ns) evidence, according
to a standardized classification already widely adopted in other
branches of clinical medicine (48) to control for potential biases.
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For instance, sensitivity analyses restricted to prospective studies
assessed whether there was evidence for risk factor pre-existing
before disorder onset, therefore controlling for reverse causation
(48). By providing the required gold-standard a priori knowledge
(44), the core results of this meta-analysis (Figures 4, 5A–E)
place the groundwork for the development of a comprehensive
polyrisk score for psychosis prediction.
The Substantial Role of Sociodemographic
Risk/Protective Factors
Most aetiopathogenic models for psychotic disorders have
focused on genetic and environmental risk factors, while
demographic factors have been investigated to a lesser degree,
presumably in the light of the fact that these factors are not strictly
modifiable. Nevertheless, the recent umbrella review found a
main effect for male gender, a main effect for 15–35 years of
age (48) and an association between psychotic disorders and
being a male aged 15–40 year-old (48). Age older than 35 was
found to be a protective factor (48). The additional risk factor
that was consistently associated with psychosis was ethnicity,
variously defined as being an ethnic minority or as having an
immigrant status or through specific categories of ethnicity.
For instance, being of a black Caribbean (OR 4.87, class I),
black African (OR 4.72), Asian (OR 2.83) or mixed (OR 2.19)
ethnicity in England or North African in Europe (OR 2.22) was
associated with an increased liability to psychosis (48). These
findings are of significant value for the development of polyrisk
scores as they suggest that these factors should always be assessed
and considered for the prediction of psychosis onset. In other
branches of medicine, age and gender are consistently used in
individualized risk scores for predicting cardiovascular diseases
(QRISK) (49), diabetes (AUSDRISK) (50) or stroke (CHA2DS2-
VASc score) (51). Recent confirmation of the clinical utility of
demographic variables for predicting psychosis onset was shown
by a recent study that included age, gender, age by gender, and
ethnicity in an individualized risk estimation tool for predicting
psychosis in secondary mental health care (34).
Parental and Perinatal Risk/Protective Factors
Psychotic syndromes are disorders of adapting to the
environment (52), which include parental, perinatal, later
risk factors, along with antecedents. The umbrella review
identified that parental factors such as paternal age (>35
OR 1.22, >45 OR 2.36), low paternal socioeconomic status
(OR 1.30) and parental history of severe mental disorder
(OR 5.94) were all associated with psychosis (48). Polygenic
studies controlling for the effect of parental risk factors found
that parental socioeconomic status accounted for 45.8% (95%CI,
36.1–55.5) of cases with schizophrenia (53). Assuming social
causation, this indicates that the impact of the environment is
actually higher than the genetic factors. Similarly, a recent study
indicated that polygenic risk scores can improve their predictive
value, explaining 17.4% variance if used in cases with a family
history of schizophrenia/psychoses (i.e., prediction by PRS
including more genetic variants) (53). These findings concur
with the need for integrating genetic and parental risk factors
for psychosis in a polyrisk score. Some studies have already
supplemented the polygenic score profile with information on
family history for psychotic disorders (54). Other risk factors
could be considered for the development of a polyrisk assessment
including urbanicity (OR 2.19) (48). As this factor was robust
and survived sensitivity analyses (class I), it should always be
measured and considered in polyrisk assessment approaches
(48). Finally, a series of perinatal risk factors were shown to
be useful for the polyrisk score. The most robust of them was
winter/spring season of birth in northern hemisphere (OR 1.04,
class III) (48), followed by diabetes in pregnancy (OR 10.12),
emergency cesarean section (OR 3.36), low birth weight (<2000
OR 2.46, <2500 OR 1.57), congenital malformations (OR
2.31), use of incubator or resuscitation (OR 2.12), threatened
premature delivery (OR 2.05), maternal obesity (OR 1.99),
uterine atony (OR 1.93), antepartum hemorrhage (0.163), and
small head circumference (OR 1.41) (48). To the best of our
knowledge, no studies have attempted to combine polygenic risk
assessment with these risk factors, and this may prove to be a
promising avenue of research.
Later Risk/Protective Factors
Later risk factors that have been associated with psychosis
include a variety of environmental risk factors such childhood
trauma (OR 2.87), problems in parental communication (OR
11.57), exposure to traffic (OR 5.55), adult life events (OR 5.34),
substance abuse such as heavy cannabis (OR 5.17), benzene (OR
3.20) or tobacco (OR 2.19), and traumatic brain injury (OR 1.49)
(48). Later risk factors also include a series of infective agents
such as IgG Toxoplasma gondii (OR 1.82), Toxocara (OR 41.61),
Chlamydia Psittaci (OR 29.05), retroviruses type W (OR 19.78),
Chlamydia pneumoniae (OR 6.02), Borna disease virus (OR
1.94), and herpes virus 2 (OR 1.44) (48). Exposures to childhood
trauma and Toxoplasma gondii were most robustly associated
with increased risk of psychosis (class III), while the other later
factors showed weak association (48).
Antecedents
There are numerous antecedent factors associated with psychosis.
The risk factor with the most robust evidence was CHR-P status
(OR 9.32, class I), followed by minor physical anomalies (OR
5.30), trait anhedonia (OR 4.41), olfactory identification ability
(OR 0.19) and premorbid IQ (0.47) (all class II) (48). Childhood
social withdrawal (OR 2.91) and non-right handedness (OR 1.58)
were also associated with increased risk of psychosis with other
antecedent factors showing weak association (48).
METHODOLOGICAL CONSIDERATIONS
FOR THE DEVELOPMENT OF A
PSYCHOSIS POLYRISK SCORE (PPS)
Specificity, Universality and Durability of
Non-genetic Risk Factors
A crucial step toward the development of a PPS is to deconstruct
and standardize the specificity of non-genetic risk factors.
While polygenic risk scores build on variation in specific
single nucleotides in exact positions in the genome, and thus
are unambiguously defined at all ages for all individuals and
thus across all studies, specificity of most non-genetic risk
factors is not completely determined. For example, some of
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FIGURE 5 | Continued
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FIGURE 5 | (A–D) Umbrella review (meta-analysis of published meta-analyses or systematic reviews published up to January 31, 2017) investigating the level of
evidence for an association of sociodemographic and parental (A), perinatal (B), later (C) risk/protective factors and antecedents (D,E) and psychotic disorders. Each
of these factors operate at the individual level. Incidence rate ratio (IRR), odds ratio (OR), risk ratio (RR), greater than one or standardized mean difference (Hedges’ g
for continuous measures) greater than zero indicated that the factor was associated with an increased likelihood of psychotic disorders. IRR, OR, and RR lower than 1
or Hedges’ g lower than zero indicated that the factor was associated with a reduced likelihood of psychotic disorders, i.e., it was protective. The level of evidence is
further stratified according to established criteria in different classes: convincing (class I), highly suggestive (class II), suggestive (class III), weak (class IV), and
non-significant (ns) evidence. The figures are based on the data from Radua et al. (48).
them may be ascertained through a multitude of instruments
of questionable comparability. Others may require contextual
specifiers (e.g., Black Caribbean Ethnicity in England), since
their predictive validity may depend on their universality in
different cultural scenarios. More on this point, other factors may
be influenced by changes in the contextual environment (e.g.,
socioeconomic status) and therefore their durability over time
periods may be questionable. An additional problem is that many
factors are affected by both genetic and non-genetic influences;
therefore the specific components of these risk factors should
also be better elucidated. For instance, the effect of parental
history of schizophrenia/psychoses is only partly mediated
through the individual’s genetic liability (54). The impact of
shared environmental influences in the context of the parental
history of severe mental illness on liability to schizophrenia
amounts to nearly 11% (55). The umbrella review has adopted
a pragmatic approach to partially mitigate the above concerns.
First, it included several meta-analyses that were conducted
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worldwide and that were representative of different contextual
environments (universality). These studies were also published
over two decades, minimizing the confounding role of time
(durability). Finally, the umbrella review indicated that despite
heterogeneous measurements (specificity) and spurious risk
factors (encompassing genetic and non-genetic components), the
factors analyzed were robustly associated with psychosis onset.
Assessment of Factors
The concurrent assessment of several demographic and
environmental risk factors for psychosis listed in Figures 5A–E
may appear logistically unviable in clinical practice. However, it
would be facilitated by a sequential testing procedure (56). For
instance, all demographic and parental risk/protective factors,
as well as some environmental (urbanicity, winter/spring season
of birth) and later risk factors (adult life events, tobacco use,
cannabis use, childhood trauma, traffic) can be self-administered
or automatically extracted from electronic medical records
or from geolocating apps that capitalize on recent e-Health
advancements. For the individuals whose predicted polyrisk of
psychosis is over a certain threshold, a clinical comprehensive
polyrisk assessment can be then performed in a sequential
fashion (56). Such an assessment may involve more accurate
testing to collect the remaining risk factors—blood sampling
for assessing the exposure to infective agents as well as to
estimate the polygenic risk, consultation of obstetric records or
by interviewing the patients’ relatives and clinical interviews.
Developmental Challenges of the PPS
The PPS can be subsequently developed for reproducing the
methodology employed to get the polygenic risk score, based on
an additive model for quantifying an individual’s genetic loading
for a disorder, as conferred by multiple risk alleles (57). From a
statistical perspective, polygenic scores are weighted sums of the
genotypes of a set of variants. To develop a PPS, the presence or
absence of each of the above risk factor should be determined
for each individual. The log of the odds ratio for each risk
factor listed in Figures 4, 5A–E can subsequently be multiplied
by either 1 (risk factor deemed present in the individual) or
0 (risk factor deemed absent). These products can successively
be added together and the sum divided by the total number of
risk factors assessed (54). Validation of this approach through
a prospective longitudinal study would be a key stage of the
development of such a tool. Furthermore, since some of the
factors are mutually exclusive or may be correlated some pruning
may be required to reduce redundancy. An additional problem
may be that missing values such as not knowing family history
in adopted individuals should be considered and potentially
imputed with statistical methods.
PSYCHOSIS POLYRISK SCORE (PPS)
PROTOTYPE
In the second part of this review we will apply the concepts
developed above to operationalize a PPS prototype.
Development and Operationalization of the
PPS
To attain the most robust prognostic tool, the umbrella review
factors were used. Factors with the greatest strength of evidence
(class I–III) were initially considered for the PPS. Since our aim
was to improve the detection of individuals at-risk for psychosis
at scale, logistical considerations were of paramount importance.
We thus applied a pragmatic filter to exclude factors that could
not easily be measured at scale (such as Toxoplasma Gondii IgG).
A total number of 13 class I–III factors that can be pragmatically
measured were included in the prototype PPS assessment. To
ensure accurate scoring, appropriate measurement and cut-offs
for each factor is of great importance. Where possible, the same
tools were selected to assess the presence of factors as used in
their respective meta-analyses in the umbrella review (48). This
was similarly true for cut-offs to preserve the validity of the Risk
Ratios. The list of included factors, along with their definitions
and the tentative cut-offs for defining each respective Risk Ratio
can be seen in Table 1. While this may not be the most predictive
set of factors in existence, one of the major characteristics of the
PPS is that it is optimizable i.e., it can be refined by the inclusion
of other predictors or by the fine tuning of the cut-offs to be used.
The PPS, similar to PRS, involves a weighted sum of exposure
to risk and protective factors, using the relative risks associated
with each factor [seen in (48)]. To construct the PPS we first
estimated a raw score for each factor as the 10-base logarithm
of its relative risk. For example, the estimated relative risk of
psychosis in individuals living in urban settings is 2.2, and thus
the raw score of the urbanity factor was log10(2.2) = 0.34. We
TABLE 1 | Operationalization of factors in the Psychosis Polyrisk Score (PPS).
Factor Operationalization Pilot cut-offs
Childhood trauma Childhood trauma questionnaire Moderate to severe
Ethnicity Self-defined Non-white ethnicity
Immigration Self-defined First- or second-generation
Premorbid IQ National adult reading test <93.6
Non-right handedness Self-defined Non-right handedness
Olfactory identification ability University of Pennsylvania smell identification test Mild microsmia
Clinical High Risk state for Psychosis Prodromal questionnaire (16-item version) >9
Urbanicity Population density of local authority Living in local administrative unit (LAU) where the majority of the
population lives in an urban center of at least 50,000 inhabitants
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then subtracted the population average of this raw score, so that
individuals at-risk would have positive scores and the remaining
individuals would have negative scores, with an average of zero.
For example, given that∼73.6% individuals live in urban settings
(and thus 26.4% in rural settings with a raw score of 0), the
population average of the urbanicity factor should be (73.6% ×
0.34) + (26.4% × 0) = 0.25. We subtracted this average from
the raw scores, i.e., the subtracted score was 0.34–0.25= 0.09 for
individuals in urban settings and 0–0.25 = −0.25 for individuals
in rural settings. Further information about prevalence data used
can be seen in Table S1. Finally, for the ease of use we multiplied
the subtracted scores by 10 and rounded them to the nearest
half integer. In the example, the final scores were 0.09 × 10
≈ 1 for individuals in urban settings and −0.25 × 10 = −2.5
for individuals in rural settings. The final scoring of the PPS is
reported in Table 2.
Furthermore, some adaptations were introduced to mitigate
for conceptual dependency across some factors. Factors related
to immigration had logical dependencies between them, i.e.,
immigrants cannot be both first-generation and second-
generation, and North African immigrants are first- or second-
generation immigrant. We combined these factors following this
logic and assuming that the proportion and extra risk of North
African immigrants is similar in first- and second-generation
immigrants (58). Factors related to ethnicity had similar logical
dependencies between them, i.e., black Caribbean is a non-white
ethnicity, and individuals cannot be from a low ethnic density
area, from a medium density area and from a high ethnic density
area at the same time.We combined these factors again following
this logic and assumed that the proportion and extra risk of black
Caribbean individuals between non-white ethnicity individuals is
similar in low, medium and high ethnic density areas.
Simulating the PPS Scores in the
Hypothetical General Population
As indicated inTable 2, an individual’s potential PPS score ranges
between−7.5 (least psychosis risk) and 32 (greatest psychosis
risk). Utilizing prevalence data for each risk factor (Table S1),
we ran 10,000,000 permutations to investigate the range and
distribution of PPS scores in the general population. While this
does require external longitudinal validation, this is the first
attempt to do this in the field. As illustrated in Figure 6, the
distribution is skewed to the left with 53.6% of individuals having
a negative PPS score (RR <1), and a further 25.7% with PPS
scores between 0 (RR= 1) and 5 (RR= 3). This leaves only 21.6%
with RR >3, with only 1.8% having an RR >30.
COMBINATION OF THE PPS WITH
POLYGENIC RISK SCORES: POTENTIALS
AND CHALLENGES
Integrating the Genetic and Non-genetic
Components
Consequently, the above-described PPS mostly includes non-
genetic risk factors. Therefore, it can be integrated with the
genetic risk score acquired in the same individuals. Integration
TABLE 2 | Scoring system for the Psychosis Polyrisk Score (PPS).
Factor PPS
Childhood trauma Yes 4
No −0.5
Ethnicity White −2
Black Caribbean In low ethnic
density area
6
In medium ethnic
density area
5.5
In high ethnic
density area
3.5
Other In low ethnic
density area
3.5
In medium ethnic
density area
3
In high ethnic
density area
1
Immigration Not immigrant −0.5
1st gen immigrant From North Africa 3
From other regions 2
2nd gen immigrant From North Africa 2.5
From other regions 1.5
Premorbid IQ <93.6 2
>93.6 −1
Non-right handedness Yes 2
No 0
Olfactory identification
ability
Yes 5.5
No −1.5
Clinical high risk state
for psychosis
>9 8.5
<9 −1.5
Urbanicity Yes 1
No −2.5
Please see Table 1 for the operationalisation of these predictors.
of genetic and non-genetic information may benefit from
considering gene by environment interactions. There is no
consensus on the most effective model. The original GWAS
meta-analysis found no epistatic or non-additive effects
between the candidate loci (38) and other studies did not find
interactions between polygenic risk score and environmental
risk factors (53, 59). On the other hand, an interaction between
polygenic risk score and demographic factors is demonstrated in
individuals of African ancestry (poor prognostic accuracy) (39)
or with a family history of psychosis (high prognostic accuracy)
(60). Since the vast majority of potential interactions across
genetic and non-genetic risk have not been tested yet (38), at
present, an additive model that sums all known genetic and
non-genetic risks is a pragmatic approximation. An additive
approach combined with weighted summation to account
for interactions has recently shown promise (61). A recent
review of gene by environment interactions confirmed that
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FIGURE 6 | Distribution of PPS scores in a hypothetical general population.
Histogram bars indicate the proportion of individuals receiving each PPS score
(in 0.5 increments) based on the prevalence of risk factors and 10,000,000
permutations. Blue dotted line illustrates the equivalent relative risk for
PPS scores.
polymorphisms of catechol-O-methyltransferase (COMT),
brain-derived neurotrophic factor (BDNF), and FK506-binding
protein 5 (FKBP5) genes might interact with early life stress and
cannabis abuse or dependence, influencing various outcomes of
schizophrenia spectrum disorders (62). In the future, robust gene
by environment interactions can be incorporated in the same way
as other combinations of risk factors were already incorporated
in the umbrella review. This would be facilitated by the proposed
comprehensive approach that assesses several candidate risk
factors and analyses them in a multivariate fashion. While this
would be the ideal target for advancing the development
of these integrated scores, with the evidence currently
available to us, the most pragmatic approach would be an
additive model.
Prognostic Modeling Challenges
The development and validation of a comprehensive genetic and
non-genetic polyrisk score is faced by some prognostic modeling
challenges. It is important to highlight that the association
measures reported by the umbrella review were based on a
univariate meta-analysis. Therefore, there is no assumption that
the reported risk or protective factors are independent, and
they could be mutually confounded. For instance, in the case
of a parental history of severe mental disorder and paternal
socioeconomic status the former could confound the impact
of the latter, or conversely, low socioeconomic status may lead
to certain mental disorders. In contrast, the polygenic risk
score is based on genetic variations that are far apart in order
to avoid linkage disequilibrium. Future studies are therefore
requested to measure multiple exposures in the same individuals,
to clarify the independence of each exposure. This should also
be facilitated by data sharing policies across ongoing studies that
would allow performing patient-data meta-analyses or umbrella
reviews. Availability of advanced statistical learning methods
(e.g., random forests, vector support machines, penalized linear
regression methods) could also help to create risk prediction
algorithms for complex multivariate situations in which multiple
collinear risk factors are involved (63). A related problem is
that the reported associative measures were all estimated in
the same pool of meta-analyses. Although the sample size
was the largest to date, and the evidence was subjected to
established classification criteria, no strict external validation in
an independent dataset was performed. As a result, PPS created
on the basis of the measures reported in the umbrella review
should be validated in independent datasets to test their actual
prognostic performance (44).
CLINICAL POTENTIAL AND FUTURE
RESEARCH
While the next decade of research will be requested to address the
above challenges, the PPS approach holds promise for resolving
the weaknesses of the CHR-P paradigm as well as to overcome
knowledge in the etiology of psychotic disorders.
Clinical Staging and Dynamic Mapping of
Developmental Risk Trajectories
The PPS approach combined with a polygenic risk score would
allow researchers to control and replicate CHR-P risk enrichment
in a controlled manner, while at the same time facilitating
identification of at-risk cases on the basis of a determinate
accumulation of risk factors. This would improve the detection of
at-risk case and refine the prediction of psychosis. Furthermore,
as illustrated in Figure 7, the PPS assessment accommodates a
clinical staging framework for the development of psychosis,
which has recently been reviewed elsewhere (3). For this aim,
it will be important to draw a distinction between individually
stable factors (genes, prenatal, and early childhood) that can
be carried forward and developmental/state factors that will
require reassessments over the life course. For instance, the PPS
assessment can potentially be administered during the preclinical
phase in non-clinical samples, such as screening programmes for
schools or non-help-seeking youths in the community (time 1)
for identifying at-risk groups and facilitate selective preventative
focused interventions (3). Such an assessment can be followed by
testing (56) in individuals who present with subtle symptoms of
psychosis-like CHR-P features in the ones accessing secondary
mental health services. Child and adolescent mental health
services and early intervention services may be particularly
suited for such an assessment (60) (Figure 7). The systematic
incorporation of a temporal dimension (64) in the polyrisk
assessment is consistent with a developmental framework for
mental disorders that has recently been recommended for
advancing etiological knowledge (65). Our group is currently
piloting a beta version of the PPS after individuals are identified
to be at-risk for psychosis by a validated transdiagnostic risk
calculator (34–36).
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Low IQ 
Normal IQ 
Other mental 
disorders risk factor  
Other protec!ve factor 
Urbanicity 
Anhedonia 
Winter/spring season of birth 
Childhood trauma/social 
withdrawal 
Infec!ous agents 
Non-right handedness 
Physical/olfactory anomalies 
Disability 
Examples of candidate
risk or protecve factors
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FIGURE 7 | Putative PPS assessment for the detection of at-risk individuals and the prediction of psychosis. Risk or protective factors that are diluted during the
pre-clinical stages may accumulate as the individual progresses across different stages until they trigger signs or symptoms and functional impairment that are
associated with help-seeking behavior and access to mental health care. In the later stages, specific aggregations of risk and protective factors may be associated
with specific clinical outcomes.
Transdiagnostic Potential for the
Prediction of Non-psychotic Mental
Disorders
There is emerging evidence that the same risk factors may be
associated with multiple types of disorders, beyond psychosis
(pleiotropy). For instance, another recent umbrella review has
indicated that childhood adversity, exposure to Toxoplasma
gondii and a history of head injury are also linked to bipolar
disorders (66). These findings do not eliminate the possibility
that even if these risk factors are shared between bipolar disorder
and psychosis, the loading and combination of factors that
results in either of the two disorders may still be constituted
of unique dimensions (65). While the risk factors themselves
may be shared with other psychiatric disorders, the weighting of
these factors will be different i.e., the same factor could have a
differential impact on risk for different disorders. What is evident
is that there is great potential for transdiagnostic research that
focuses on broad and heterogeneous samples of mental disorders.
Unfortunately, to date, transdiagnostic research has been poorly
operationalized and has not provided robust evidence to improve
the current classification system (67).
The Role of Biomarkers
In the current perspective, we selectively focused on genetic
and non-genetic factors, while biomarkers were not primarily
discussed. One of our aims was to improve the modest
detection power of the CHR-P paradigm and the use of
biomarkers would present specific challenges that would
require a separate manuscript. For example, risk stratification
models that include neuroimaging, electrophysiological, or
peripheral biomarkers (68–70) have been mostly developed
and validated within CHR-P samples (56). Therefore,
these models could not be used to improve the detection
of at-risk individuals. Furthermore, their broader use in
the community or National Health Service scenarios is
hampered by feasibility and economic caveats, because these
models are logistically complex. Our group has recently
demonstrated that risk stratification models encompassing
neuroimaging, electrophysiological and peripheral biomarkers
could rather be used in subsequent testing, in line with similar
stepped risk enrichment assessments that are used in clinical
medicine (56).
CONCLUSIONS
The combination of risk/protective factors encompassing genetic
(PRS) and non-genetic information (PPS) holds promise
for overcoming the epidemiological weakness of the CHR-P
paradigm. The PPS conceptually and empirically developed here
will facilitate future research in this field and hopefully advance
our ability to detect individuals at-risk for psychosis and forecast
their clinical outcomes.
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